2025 · Poster Presentation · Pharma Partner · Hepatology
34
Total Publications
15
Abstract/Manuscript
2
Oral Presentation
17
Poster Presentation
2025 · Abstract/Manuscript · Yes
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH.
Read more →2025 · Abstract/Manuscript · Derek Gazis
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease.
Read more →2025 · Abstract/Manuscript · Yes
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.
Read more →2025 · Poster Presentation · Pharma Partner · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups.
Read more →2024 · Poster Presentation · Yes · Hepatology
Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality.
Read more →2024 · Poster Presentation · University of Birmingham (UK) · Hepatology
Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH.
Read more →2024 · Poster Presentation · University of Birmingham (UK) · Hepatology
A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Non-invasive tests as a prediction tool to assess MASH resolution score.
Read more →2024 · Poster Presentation · Derek Gazis · Hepatology
A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH.
Read more →2024 · Abstract/Manuscript · Duke
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort.
Read more →2024 · Abstract/Manuscript · Yes
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH.
Read more →2024 · Oral Presentation · Yes · Hepatology
Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality.
Read more →2023 · Abstract/Manuscript · Yes
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.
Read more →2023 · Abstract/Manuscript · Pharma Partner
Impact of itch on quality of life in people with primary biliary cholangitis: a plain language summary.
Read more →2023 · Oral Presentation · Derek Gazis · Hepatology
Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study.
Read more →2022 · Poster Presentation · Yes · Hepatology
The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH.
Read more →2022 · Poster Presentation · Yes · Methods/Pharmacoepi
Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19.
Read more →2022 · Abstract/Manuscript · Emory
Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.
Read more →2022 · Abstract/Manuscript · Pharma Partner
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis.
Read more →2021 · Poster Presentation · Pharma Partner · Hepatology
Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study.
Read more →2021 · Abstract/Manuscript · Pharma Partner
Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis.
Read more →2021 · Abstract/Manuscript · Yes
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study.
Read more →2021 · Abstract/Manuscript · Yes
Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort.
Read more →2021 · Abstract/Manuscript · Yes
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
Read more →2021 · Abstract/Manuscript · Yes
Factors Associated with Readmission in the US Following Hospitalization with COVID-19.
Read more →2020 · Poster Presentation · University of Birmingham (UK) · Hepatology
Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice.
Read more →2020 · Poster Presentation · Yes · Hepatology
Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study.
Read more →2020 · Abstract/Manuscript · Yes
Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States.
Read more →2019 · Poster Presentation · Yes · Methods/Pharmacoepi